Indivior

To change patients' lives by ensuring all have access to evidence-based treatment for addiction and co-occurring disorders.

Indivior SWOT Analysis

Updated: October 5, 2025 • 2025-Q4 Analysis

How to Use This Analysis

This analysis for Indivior was created using Alignment.io™ methodology - a proven strategic planning system trusted in over 75,000 strategic planning projects. We've designed it as a helpful companion for your team's strategic process, leveraging leading AI models to analyze publicly available data.

While this represents what AI sees from public data, you know your company's true reality. That's why we recommend using Alignment.io and The System of Alignment™ to conduct your strategic planning—using these AI-generated insights as inspiration and reference points to blend with your team's invaluable knowledge.

Powered by Leading AI Models

Anthropic

Industry-leading reasoning capabilities with 200K context window for comprehensive analysis

Google Gemini

State-of-the-art multimodal intelligence with real-time market data processing and trend analysis

OpenAI GPT

Advanced reasoning with comprehensive industry knowledge and strategic problem-solving capabilities

The Indivior SWOT analysis reveals a company at a pivotal juncture, skillfully leveraging its blockbuster SUBLOCADE® to achieve market dominance and financial strength. This success, however, creates a critical concentration risk, with over-reliance on a single product and geography. The strategic imperative is clear: Indivior must use its current strength as a launchpad for aggressive global expansion and pipeline diversification. Opportunities in adjacent CNS markets and growing public focus on addiction are significant tailwinds. However, threats from new competitors and persistent payer pressures require immediate, focused action. The company's future hinges on its ability to translate SUBLOCADE®'s momentum into a broader, more resilient portfolio, transforming from a single-product success story into a durable leader in treating complex brain disorders. The next 24 months are crucial for executing this strategic diversification.

Alkermes Braeburn Inc. Teva Pharmaceutical Viatris Johnson & Johnson

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To change patients' lives by ensuring all have access to evidence-based treatment for addiction and co-occurring disorders.

Toggle Theme

Strengths

DOMINANCE: SUBLOCADE®'s >$1B run rate and ~70% US LAI market share.
FOCUS: Deep scientific and commercial expertise in addiction medicine.
FINANCIALS: Strong balance sheet with $213M net income in FY23.
PIPELINE: ATRIGEL® delivery tech and new assets like OPVEE® spray.
ACCESS: Established payer relationships and patient support programs.

Weaknesses

CONCENTRATION: Over 75% of revenue from SUBLOCADE®, creating risk.
GEOGRAPHY: Heavy reliance on the US market for nearly all revenues.
REPUTATION: Lingering brand perception issues from historical litigation.
PIPELINE-GAP: Lack of a guaranteed near-term blockbuster successor.
MANUFACTURING: Dependence on third-party CMOs for critical supply chain.

Opportunities

GLOBALIZATION: Significant untapped SUBLOCADE® market in Europe & APAC.
DIVERSIFICATION: M&A in adjacent CNS fields like schizophrenia/depression.
AWARENESS: Growing government focus on funding addiction treatment.
LABEL: Potential SUBLOCADE® label expansion for new patient populations.
DIGITAL: Using digital health tools to improve patient adherence/outcomes.

Threats

COMPETITION: New LAI entrants like Braeburn's Brixadi gaining traction.
PAYERS: Increasing pricing pressure and reimbursement hurdles from PBMs.
LITIGATION: Ongoing risk of lawsuits related to the broader opioid crisis.
REGULATION: Potential for government price controls on pharmaceuticals.
GENERIC: Future patent cliffs for key products post-2025 could be a risk.

Key Priorities

GLOBALIZE: Accelerate SUBLOCADE® ex-US growth to diversify revenue.
INNOVATE: Aggressively advance pipeline and pursue M&A to reduce risk.
DEFEND: Reinforce US SUBLOCADE® leadership against new competitors.
OPTIMIZE: Strengthen payer value propositions to protect pricing/access.

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Indivior OKR

Updated: October 5, 2025 • 2025-Q4 Analysis

The Indivior OKR plan is a focused and potent strategic blueprint for growth. It correctly identifies the core tension: leveraging current dominance while urgently de-risking the future. The objectives—GLOBALIZE, INNOVATE, DEFEND, OPTIMIZE—are sharp, ambitious, and directly address the highest-priority conclusions from the SWOT analysis. The Key Results are well-constructed, balancing growth initiatives (ex-US expansion, M&A) with defensive measures (market share protection, payer partnerships). This plan provides exceptional clarity, aligning the entire organization on a critical mission: to transform today's single-product strength into a diversified, global, and durable leadership position in CNS disorders. Success here will define Indivior's next decade.

Alkermes Braeburn Inc. Teva Pharmaceutical Viatris Johnson & Johnson

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To change patients' lives by ensuring all have access to evidence-based treatment for addiction and co-occurring disorders.

GLOBALIZE SUBLOCADE®

Establish SUBLOCADE® as the undisputed global OUD leader.

GROWTH: Increase ex-US net revenue from 5% to 15% of total SUBLOCADE® sales to diversify our income stream.
LAUNCH: Secure reimbursement and launch in 3 new key international markets, expanding our global patient reach.
DEFEND: Maintain over 65% market share in the US LAI for OUD segment by strengthening our value proposition.
EVIDENCE: Publish two real-world evidence studies demonstrating long-term value to support global payer talks.

INNOVATE BEYOND

Build a powerful, diversified CNS pipeline for future growth.

PIPELINE: Advance two non-OUD pipeline assets into the next clinical trial phase to show portfolio progress.
ACQUIRE: Complete one strategic acquisition or licensing deal in a complementary CNS area to add new technology.
DISCOVERY: Initiate three AI-driven drug discovery pilot programs to build a foundation for future innovation.
PARTNER: Establish a new academic or biotech partnership to access novel scientific platforms and targets.

DEFEND THE CORE

Reinforce our US market leadership against all competitors.

COMPETE: Achieve a >3:1 market share ratio against our nearest LAI competitor in the US OUD market.
ADOPTION: Increase the number of unique US prescribers for PERSERIS® by 25% to grow our schizophrenia franchise.
LAUNCH: Ensure OPVEE® achieves preferred status on 50% of targeted national payer formularies within 12 months.
VOICE: Achieve #1 share of voice in addiction medicine digital channels through targeted educational content.

OPTIMIZE ACCESS

Create unbreakable partnerships with payers and providers.

FORMULARY: Secure unrestricted access for SUBLOCADE® across 85% of commercial and Medicaid lives in the US.
VALUE: Launch two new value-based contract models with major national payers, linking price to outcomes.
SUPPORT: Reduce average patient onboarding time through our InSupport® hub by 20% to improve experience.
ADHERENCE: Deploy a new AI-enhanced digital tool to our patient support services to improve treatment adherence.

METRICS

SUBLOCADE® Net Revenue Growth: Target +20% YoY
Non-SUBLOCADE® Revenue %: Grow from <15% to 25% of total
Adjusted Net Income: Target >$250M

VALUES

Focus on patient needs to drive decisions
Seek and celebrate diversity
Act with integrity and accountability
Work collaboratively
Strive for excellence in all we do

Build strategic OKRs that actually work. AI insights meet beautiful design for maximum impact.

Get Free OKR Template

Indivior Retrospective

AI-Powered Insights

Claude

Gemini

GPT

Indivior PLC 2023 Annual Report
Indivior PLC Q3 2024 Earnings Release & Presentation
Indivior Corporate Website (indivior.com)
SEC Filings and Investor Relations materials
Pharmaceutical industry market research reports
Public financial data sources (e.g., Yahoo Finance)

Alkermes Braeburn Inc. Teva Pharmaceutical Viatris Johnson & Johnson

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To change patients' lives by ensuring all have access to evidence-based treatment for addiction and co-occurring disorders.

Toggle Theme

What Went Well

SUBLOCADE®: US net revenue growth continued to exceed market expectations.
MARGINS: Maintained strong gross margins despite inflationary pressures.
PIPELINE: Achieved key regulatory milestone with OPVEE® FDA approval.
CASHFLOW: Generated robust operating cash flow, strengthening balance sheet.
EXECUTION: Commercial team successfully defended market share from new entrants.

Not So Well

GUIDANCE: Initial caution on full-year guidance created investor uncertainty.
GLOBAL: Slower than anticipated revenue ramp-up in ex-US markets.
SG&A: Increased spending on commercial activities impacted operating leverage.
PERSERIS®: Slower uptake for the schizophrenia drug than initially hoped.
DIVERSIFICATION: Revenue base remains highly concentrated on one product.

Learnings

MARKET: The US OUD market is resilient but approaching saturation.
PAYERS: Payer negotiations are becoming more challenging and critical.
EXPANSION: International market development requires significant upfront investment.
COMPETITION: New entrants are a real threat that requires constant vigilance.
PORTFOLIO: A broader portfolio is essential for sustainable long-term growth.

Action Items

INVEST: Increase targeted investment in key ex-US markets to drive growth.
ACCELERATE: Speed up business development activities for pipeline assets.
COMMUNICATE: Develop stronger value-based arguments for payers.
OPTIMIZE: Refine US commercial strategy for PERSERIS® to boost adoption.
REPORT: Provide more granular reporting on pipeline progress to investors.

Run better retrospectives in minutes. Get insights that improve your team.

Get Free Retro Template

Organization	SWOT Analysis	OKR Plan	Top 6	Retrospective

Explore specialized team insights and strategies

Indivior Market

AI-Powered Insights

Claude

Gemini

GPT

Indivior PLC 2023 Annual Report
Indivior PLC Q3 2024 Earnings Release & Presentation
Indivior Corporate Website (indivior.com)
SEC Filings and Investor Relations materials
Pharmaceutical industry market research reports
Public financial data sources (e.g., Yahoo Finance)

Founded: 2014 (demerged from Reckitt Benckiser)
Market Share: Leading share (~70%) of US long-acting injectable OUD market.
Customer Base: Physicians, treatment centers, hospitals, and government health systems.
Category:
Pharmaceuticals
SIC Code: 2834
NAICS Code: 325412 Pharmaceutical Preparation Manufacturing
Location: North Chesterfield, Virginia
Zip Code: 23235
Congressional District: VA-1 HENRICO
Employees: 1000

Competitors

Alkermes View Analysis

Braeburn Inc. Request Analysis

Teva Pharmaceutical Request Analysis

Viatris View Analysis

Johnson & Johnson View Analysis

Products & Services

No products or services data available

Distribution Channels

Indivior Business Model Analysis

AI-Powered Insights

Claude

Gemini

GPT

Indivior PLC 2023 Annual Report
Indivior PLC Q3 2024 Earnings Release & Presentation
Indivior Corporate Website (indivior.com)
SEC Filings and Investor Relations materials
Pharmaceutical industry market research reports
Public financial data sources (e.g., Yahoo Finance)

Problem

High relapse rates in Opioid Use Disorder
Burden of daily medication for patients
Diversion risk of oral buprenorphine
Stigma associated with addiction treatment

Solution

Once-monthly injectable (SUBLOCADE®)
Patient support services (InSupport®)
HCP education and training programs
Novel overdose reversal agent (OPVEE®)

Key Metrics

SUBLOCADE® net revenue and patient volume
Pipeline advancement milestones
Ex-US revenue as a % of total revenue
Operating income and cash flow

Unique

Market-leading LAI buprenorphine product
Deep expertise in addiction science
Established commercial channel in OUD
ATRIGEL® delivery system technology

Advantage

Strong patent portfolio for SUBLOCADE®
Brand recognition and physician trust
Economies of scale in manufacturing
Regulatory expertise with the FDA/DEA

Channels

Specialty Pharmacies and Distributors
Direct sales force to HCPs/clinics
Government contracts (VA, etc.)
Digital marketing and medical education

Customer Segments

Addiction specialists and psychiatrists
Hospitals and integrated health networks
Government payers (Medicaid, VA)
Commercial health insurance plans

Costs

Research & Development for new assets
Sales, General & Admin (SG&A) expenses
Cost of Goods Sold (COGS) via CMOs
Litigation and compliance expenses

Indivior Product Market Fit Analysis

Updated: October 5, 2025

Indivior helps patients reclaim their lives from addiction. It provides a once-monthly injectable treatment that removes the daily burden of medication and is clinically proven to help sustain abstinence. This allows patients to focus on their recovery, rebuilding their work, and reconnecting with their families, offering a real path back to a stable and productive life.

SUSTAINED ABSTINENCE: Empowering long-term recovery with proven science.

REDUCED BURDEN: Simplifying treatment to a single monthly injection.

RECLAIMED LIVES: Enabling patients to focus on life, not medication.

Before State

Daily burden of taking medication
Constant cravings and relapse risk
Stigma of addiction treatment
Instability in work and relationships

After State

Freedom from daily dosing decisions
Sustained blockade of opioid effects
Discreet and professional treatment
Opportunity to rebuild a stable life

Negative Impacts

High risk of overdose and death
Social and economic marginalization
Strain on healthcare systems
Disruption to family and community

Positive Outcomes

Increased days of abstinence from illicit opioids
Improved patient retention in treatment programs
Reduced healthcare costs from ER visits
Enhanced quality of life and functionality

Key Metrics

Customer Retention Rates

High due to monthly injection cycle (~85%).

Net Promoter Score (NPS)

Estimated 50-60 among prescribing physicians.

User Growth Rate

SUBLOCADE® US patient growth ~20% YoY.

Customer Feedback/Reviews

Positive physician feedback on efficacy.

Repeat Purchase Rates

Strong, driven by chronic nature of OUD.

Requirements

Physician training on injection administration
Payer coverage and reimbursement support
Patient education and adherence programs
Robust specialty pharmacy distribution network

Why Indivior

Monthly injection of SUBLOCADE® by a HCP
Comprehensive patient support hub (InSupport®)
Targeted marketing to addiction specialists
Ongoing clinical data generation

Indivior Competitive Advantage

Once-monthly dosing improves adherence vs daily
Proven efficacy in reducing illicit opioid use
Reduces risk of diversion of medication
Deep expertise in the addiction treatment field

Proof Points

FDA approval based on robust Phase 3 trials
Blockbuster drug status with >$1B annual sales
Endorsement by addiction medicine key opinion leaders
Preferred status on many payer formularies

Indivior Market Positioning

AI-Powered Insights

Claude

Gemini

GPT

Indivior PLC 2023 Annual Report
Indivior PLC Q3 2024 Earnings Release & Presentation
Indivior Corporate Website (indivior.com)
SEC Filings and Investor Relations materials
Pharmaceutical industry market research reports
Public financial data sources (e.g., Yahoo Finance)

Strategic pillars derived from our vision-focused SWOT analysis

Drive global adoption and defend OUD leadership.

Advance pipeline and acquire tech in mental health.

Deepen payer relationships and patient support systems.

Grow commercial footprint beyond the US market.

What You Do

Develops and commercializes treatments for addiction and mental illness.

Target Market

Patients suffering from Opiate Use Disorder (OUD) and Schizophrenia.

Differentiation

Market-leading long-acting injectable (LAI) for OUD.
Deep scientific and commercial expertise in addiction medicine.

Revenue Streams

Pharmaceutical product sales
Licensing and partnership agreements

Indivior Operations and Technology

AI-Powered Insights

Claude

Gemini

GPT

Indivior PLC 2023 Annual Report
Indivior PLC Q3 2024 Earnings Release & Presentation
Indivior Corporate Website (indivior.com)
SEC Filings and Investor Relations materials
Pharmaceutical industry market research reports
Public financial data sources (e.g., Yahoo Finance)

Company Operations

Organizational Structure: Global matrix structure by function and geography.
Supply Chain: Relies on third-party contract manufacturing organizations (CMOs).
Tech Patents: Portfolio of patents covering SUBLOCADE® and other pipeline assets.
Website: https://www.indivior.com

Top Clients

Board Members

Indivior Competitive Forces

Threat of New Entry

LOW: High barriers to entry due to extensive R&D costs, complex clinical trials, regulatory hurdles (FDA/DEA), and patent protection.

Supplier Power

MODERATE: Reliance on a limited number of specialized CMOs for complex LAI manufacturing gives them some pricing leverage.

Buyer Power

HIGH: Large payers, PBMs, and government bodies exert significant pressure on pricing and formulary access, demanding rebates.

Threat of Substitution

MODERATE: Oral medications are a constant, cheaper alternative. Novel future treatments (e.g., psychedelics) are a long-term risk.

Competitive Rivalry

MODERATE: High rivalry from Alkermes (Vivitrol) & Braeburn (Brixadi). Generic oral films create price pressure at the low end.

Analysis of AI Strategy

Updated: October 5, 2025 • 2025-Q4 Analysis

The Indivior AI SWOT analysis highlights a significant opportunity to build a durable competitive advantage by embedding AI into its core operations. The company's primary strength is its rich, domain-specific clinical data, a valuable asset for training targeted AI models in addiction and mental health. However, this is counterbalanced by weaknesses in internal AI talent and data infrastructure. To win, Indivior must prioritize using AI to accelerate its weakest link: the R&D pipeline. By focusing on AI for novel drug discovery and clinical trial optimization, it can directly address its strategic vulnerability of product concentration. Simultaneously, enhancing patient engagement with AI will fortify its commercial leadership. The strategy should be to partner for discovery, build for commercial optimization, and invest in a unified data foundation to power both initiatives.

Alkermes Braeburn Inc. Teva Pharmaceutical Viatris Johnson & Johnson

No past cycles

Mission & Vision SWOT Analysis OKR Plan Retrospective AI Strategy Data Acquisition

To change patients' lives by ensuring all have access to evidence-based treatment for addiction and co-occurring disorders.

Strengths

DATA: Rich, structured clinical trial data for OUD and schizophrenia.
DOMAIN: Deep subject matter expertise to guide AI model development.
FOCUS: Niche therapeutic areas allow for highly targeted AI applications.
PARTNERSHIPS: Potential to partner with AI-first drug discovery firms.
ASSETS: Existing digital patient support hubs can be AI-enhanced.

Weaknesses

TALENT: Lack of in-house AI/ML engineering and data science expertise.
INFRASTRUCTURE: Limited scalable cloud computing and data platforms.
DATA-SILOS: Patient and commercial data is likely fragmented across systems.
CULTURE: Traditional pharma culture may be slow to adopt AI workflows.
SCALE: Insufficient volume of real-world evidence data for some models.

Opportunities

DISCOVERY: AI to identify novel drug targets for addiction/mental illness.
OPTIMIZATION: AI-driven clinical trial design to reduce time and cost.
ADHERENCE: Predictive models to identify patients at risk of non-adherence.
COMMERCIAL: AI to optimize marketing spend and sales force effectiveness.
DIAGNOSTICS: Partnering on AI-powered tools for earlier disease detection.

Threats

PRIVACY: Strict HIPAA/GDPR regulations create high compliance hurdles.
BIAS: AI models trained on non-diverse data could worsen health inequity.
REGULATION: FDA and EMA are still developing frameworks for AI in pharma.
COMPETITION: Larger pharma rivals are investing heavily in AI capabilities.
COST: Significant investment required for talent and infrastructure.

Key Priorities

DISCOVERY: Initiate pilot projects using AI for novel target identification.
EFFICIENCY: Leverage AI to optimize clinical trial recruitment and design.
ENGAGEMENT: Enhance patient support programs with AI-driven personalization.
FOUNDATION: Build foundational data infrastructure and hire key AI talent.

Create professional SWOT analyses in minutes with our AI template. Get insights that drive real results.

Get Free SWOT Analysis Template

Indivior Financial Performance

AI-Powered Insights

Claude

Gemini

GPT

Indivior PLC 2023 Annual Report
Indivior PLC Q3 2024 Earnings Release & Presentation
Indivior Corporate Website (indivior.com)
SEC Filings and Investor Relations materials
Pharmaceutical industry market research reports
Public financial data sources (e.g., Yahoo Finance)

Profit: FY 2023 Net Income: $213 Million

Market Cap: Approx. $2.1 Billion (as of late 2024)

Stock Performance

Annual Report: Available on the corporate website under 'Investors'.

Debt: Net cash position; minimal long-term debt.

ROI Impact: Shareholder returns tied to SUBLOCADE® performance and pipeline news.

SWOT Index

Composite strategic assessment with 10-year outlook

/ 100

Market Leader

ICM Index

STRATEGIC ADVISOR ASSESSMENT

Indivior scores as a strong Market Leader with a clear, socially impactful mission (Ambition: 85). Its Achievability is solid but capped by heavy product concentration. The SWOT is perfectly balanced, reflecting a company leveraging immense strength (SUBLOCADE®) to fund its fight against significant risks (competition, diversification). The OKRs are well-aligned but focus more on category-shaping than world-shaping moves. The low growth multiplier reflects the challenge of moving beyond a saturated core market.

SWOT Factors

Upside: 83.3 Risk: 83.3

OKR Impact

AI Leverage

Top 3 Strategic Levers

Accelerate M&A to diversify the pipeline and de-risk revenue.

Drive aggressive ex-US expansion to find new growth vectors.

Leverage AI in drug discovery to create a sustainable R&D edge.

AI Disclosure

This report was created using the Alignment Method—our proprietary process for guiding AI to reveal how it interprets your business and industry. These insights are for informational purposes only and do not constitute financial, legal, tax, or investment advice.

Next Step

Want to see how the Alignment Method could surface unique insights for your business?

Request your custom report Contact our team

About Alignment LLC

Alignment LLC specializes in AI-powered business analysis. Through the Alignment Method, we combine advanced prompting, structured frameworks, and expert oversight to deliver actionable insights that help companies understand how AI sees their data and market position.